Mechanism of the neuroprotective effect of GLP-1 in a rat model of Parkinson’s with pre-existing diabetes.

Mechanism of the neuroprotective effect of GLP-1 in a rat model of Parkinson’s with pre-existing diabetes.

Publication date: Dec 01, 2019

Several studies have suggested the association between neurodegenerative diseases and diabetes mellitus (DM), DM causes cognitive impairment with age, but its effect is not well known in Parkinson’s disease (PD). As a member of the incretin family, Glucagon-like peptide-1 (GLP-1) has glycemic regulation functions. It also exerts many additional effects on different tissues through its receptor’s widespread expression.

our aim is to investigate the effect of pre-existing diabetes on the severity of PD in male albino rats, and to find out whether GLP-1 could improve PD symptoms in diabetic animals in addition to its hypoglycemic effect, and how it could do that.

75 adult male albino rats were equally divided into: Control, Parkinson’s, Diabetic Parkinson’s, Diabetic Parkinson’s + low dose exenatide (GLP-1 receptor agonist), Diabetic Parkinson’s + high dose exenatide group. Blood glucose and insulin, striatal dopamine, some striatal oxidative stress and inflammatory markers, and the catalepsy score were measured.

Pre-existing of diabetes before initiation of PD raises the severity of PD shown by the more significant increase in catalepsy score, and the more significant decrease in striatal dopamine level. GLP-1 effects extend beyond their hypoglycemic effects only since it has a direct anti-oxidant, and anti-inflammatory neuronal effect with increasing the striatal dopamine and improving the catalepsy score in a dose dependent manner.

Diabetes increases the severity of impairment in PD, and GLP-1 improve it through its direct neuronal effect in addition to its indirect effect through producing hypoglycemia.

Elbassuoni, E.A. and Ahmed, R.F. Mechanism of the neuroprotective effect of GLP-1 in a rat model of Parkinson’s with pre-existing diabetes. 23126. 2019 Neurochem Int (131):

Concepts Keywords
Agonist Neurodegenerative diseases diabetes
Albino Significant increase catalepsy
Catalepsy Organ systems
Cognitive Impairment Hormones
Diabetes RTT
Diabetes Mellitus Endocrine system
Diabetic Peptide hormones
DM Anorectics
Dopamine Incretin
Exenatide Exenatide
Glucagon Diabetes
Glucose Hypoglycemia
Hypoglycemia Glucagon
Hypoglycemic
Incretin
Insulin
Neurodegenerative Diseases
Neuroprotective
Oxidant
Oxidative Stress
Parkinson
Peptide
Receptor
Striatal

Semantics

Type Source Name
disease MESH neurodegenerative diseases
disease MESH diabetes mellitus
disease MESH cognitive impairment
drug DRUGBANK Glucagon
drug DRUGBANK Exenatide
drug DRUGBANK Dextrose unspecified form
drug DRUGBANK Dopamine
disease MESH oxidative stress
disease MESH catalepsy
disease MESH hypoglycemia

Similar

Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *